فهرست نشریات علمی دسترسی آزاد ایران

Objective: Ibuprofen – a non‑steroidal anti‑inflammatory drug (NSAID)‑ and glucosaminesulfate – a natural compound and a food supplement‑ are two therapeutic agents which havebeen widely used for treatment of patients with temporomandibular joint (TMJ) disorders.This study was aimed to compare the effectiveness and safety of these two medications inthe treatment of patients suffering fromTMJ disorders.Methods: After obtaining informed consent, 60 patients were randomly allocated to twogroups. Patients with painful TMJ,TMJ crepitation or limitation of mouth opening enteredthe study. Exclusion criteria were history of depressive disorders, cardiovascular disease,musculoskeletal disorders, asthma, gastrointestinal problems, kidney or liver dysfunctionor diabetes mellitus, dental diseases needing ongoing treatment; taking aspirin or warfarin,or concomitant treatment of TMJ disorder with other agents or methods.Thirty patientswere treated with ibuprofen 400  mg twice a day,  (mean age 27.12  ±  10.83  years) and30 patients (mean age 26.60 ± 10) were treated with glucosamine sulfate 1500 mg daily.Patients were visited 30, 60 and 90 days after starting the treatment, pain and mandibularopening were checked and compared within and between two groups.Findings: Comparing with baseline measures, both groups had significantly improvedpost‑treatment pain (P < 0.0001 for both groups) and mandibular opening (P value: 0.001for glucosamine sulfate and 0.03 for ibuprofen).Post treatment pain and mandibular openingshowed significantly more improvement in the glucosamine treated patients (P < 0.0001 and0.01 respectively).Rate of adverse events was significantly lower in the P value glucosaminesulfate group (P < 0.0001).Conclusion: This investigation demonstrated that comparing with a commonly prescribedNSAID – ibuprofen‑, glucosamine sulfate is a more effective and safer therapeutic agent fortreatment of patients with TMJ degenerative join disorder.